Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

10,506articles mentioning drugs

58,393drug mentions

9,496distinct drugs extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted drugs

Showing 7,621–7,680 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.

angiotensin II1 angiotensin II inhibitors1 angiotensin II receptor blocker1 angiotensin converting enzyme (ACE) inhibitor1 angiotensin converting enzyme inhibitors-angiotensin II receptor blockers1 anifrolumabAbstract1 anlotinib-induced1 antacid1 anthelmintic medication1 anthelmintics1 anti PD-11 anti-4-1BB1 anti-B7-H3 antibody‒drug conjugate1 anti-BAFF1 anti-CD38 mAb1 anti-CD38 monoclonal antibodies1 anti-CD401 anti-CD40 agonist antibody1 anti-CD47 monoclonal antibody1 anti-CGRP monoclonal antibodies1 anti-CTLA-4 antibody1 anti-CTLA-4 mAb1 anti-CTLA4 antibody1 anti-HER2 antibody-drug conjugates1 anti-Ly6G1 anti-MDA5 antibody1 anti-Mullerian Hormone1 anti-Müllerian hormone1 anti-OA pharmacological agents1 anti-OX401 anti-PD-(L)1-based1 anti-PD-1 ICB1 anti-PD-L1 avelumab1 anti-Parkinson’s drugs1 anti-Sjögren’s syndrome antigen A1 anti-TIM-31 anti-Th/To-positive1 anti-VEGF agents1 anti-VEGFR21 anti-anginal medication1 anti-cancer compounds1 anti-cytotoxic T lymphocyte-associated antigen-4 immune checkpoint inhibitors1 anti-diabetic agents1 anti-fibrotic medications1 anti-histamines1 anti-hypertensive drugs1 anti-infectious agents1 anti-inflammatory drugs1 anti-inflammatory reliever1 anti-interferon1 anti-oestrogen medications1 anti-pan γδ x CD1231 anti-pan γδ x CD123 bispecific antibody1 anti-programmed cell death protein 11 anti-programmed cell death protein 1 (PD1)1 anti-programmed cell death protein-1/programmed death-ligand 11 anti-programmed death (ligand) 11 anti-programmed death-ligand 1 (PD-(L)1)1 anti-programmed death-ligand 1 (PD-L1)1 anti-programmed death-ligand 1 antibodies1

View all 9,496 drugs on one page

Articles mentioning drugs

10,506 articles · page 46 of 876

4CPS-237 Centred analysis of pharmaceutical interventions on high-alert medications in an emergency department

ejhpharm · abstract · 2026-03-18 · 15 matching annotations

95.0%

insulins OAC digoxin opioids benzodiazepines HAM-H HAMs Institute for Safe Medication Practices chronic pathology

…ineoplastic/immunomodulators) =2.9%. Drugs mainly involved were insulins (22.9%), benzodiazepines (20.0%), OAC (11.4%), opioids (8.6%), …

4CPS-242 Melanoma and immunotherapy: clinical aspects and feedback on medico-economic challenges in a hospital centre

ejhpharm · abstract · 2026-03-18 · 15 matching annotations

99.2%

Pembrolizumab Nivolumab Ipilimumab melanoma

…t saving of €11,000 per patient when using Nivolumab instead of Pembrolizumab, with equivalent efficacy. This finding supports a review of pr…

4CPS-259 Impact of switching to biosimilar etanercept in rheumatoid arthritis patients followed in pharmaceutical consultations at a tertiary hospital

ejhpharm · abstract · 2026-03-18 · 15 matching annotations

98.0%

Erelzi Benepali Enbrel etanercept Rheumatoid arthritis RA EQ-5D

…nt, and 43% worsening in perceived health status post-switch to Erelzi. Ten suspected adverse drug reactions were reported since IPC i…

4CPS-316 Indirect treatment comparison of anti-PD-1/L1 plus chemotherapy in advanced or recurrent endometrial cancer with proficient mismatch repair

ejhpharm · abstract · 2026-03-18 · 15 matching annotations

98.6%

durvalumab Pembrolizumab dostarlimab atezolizumab Olaparib pMMR endometrial cancer

…erapy –specifically those including pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezolizumab–, in the treatment …

5PSQ-064 Immunomediated toxicity associated with immune checkpoint inhibitors

ejhpharm · abstract · 2026-03-18 · 15 matching annotations

99.4%

avelumab nivolumab pembrolizumab atezolizumab durvalumab ipilimumab cemiplimab autoimmune diseases arthritis

…receiving durvalumab, 25% receiving cemiplimab, 66.7% receiving avelumab, and 60% receiving the ipilimumab and nivolumab. A 61.5% of irA…

5PSQ-093 Myocarditis-myositis-myasthenia gravis overlap syndrome: an emerging severe adverse reaction among immune checkpoint inhibitors. Analysis of reports in the Spanish adverse reactions database (FEDRA)

ejhpharm · abstract · 2026-03-18 · 15 matching annotations

99.2%

pembrolizumab nivolumab ipilimumab myasthenia gravis myositis-myocarditis-myasthenia gravis

…ortal outcome) as a suspected ADR of different ICIs (nivolumab, pembrolizumab and nivolumab+ipilimumab) within 2 months in the regional Pharm…

6ER-013 Indirect comparison of pembrolizumab plus enfortumab vedotin and nivolumab plus gemcitabine-cisplatin in urothelial carcinoma

ejhpharm · abstract · 2026-03-18 · 15 matching annotations

96.4%

Nivolumab-CT nivolumab gemcitabine-cisplatin pembrolizumab EV-Pembrolizumab enfortumab vedotin gemcitabine urothelial carcinoma European Medicines Agency UC

…0 (95% CI, 0.45-0.81; p=0.0009) between EV-Pembrolizumab versus Nivolumab-CT. According to the ATE guide, these treatments presented a degre…

6ER-014 Treatments for PIK3CA-mutated in advance or metastatic breast cancer: a systematic review

ejhpharm · abstract · 2026-03-18 · 15 matching annotations

90.5%

Buparlisib alpelisib buparlisib with paclitaxel ipatasertib with paclitaxel capivasertib with paclitaxel taselisib with fulvestrant capivasertib plus fulvestrant pictilisib plus fulvestrant fulvestrant buparlisib plus fulvestrant+1 more

…3-50.7); PFS=12.8 months (95% CI 6.6-18.8); ORR=not available]. Buparlisib plus fulvestrant presented the next best numerical efficacy [OS…

6ER-023 Integrating FDA approved app based prescription digital therapeutic apps into clinical practice

ejhpharm · abstract · 2026-03-18 · 15 matching annotations

92.2%

PDTx Regulora Somryst DaylightRx CT-132 AspyreRx™Rejoyn Type 2 diabetes Irritable bowel syndrome Major depressive disorder

…ining exercises, and gut-directed hypnotherapy. Since App-based PDTx are not typical pharmaceutical agents; they may create complexi…

PO:04:108 From B-cell blockade to interferon inhibition: achieving remission in refractory systemic lupus erythematosus

lupusscimed · abstract · 2026-03-01 · 15 matching annotations

98.0%

prednisolone methotrexate hydroxychloroquine belimumab anifrolumab mycophenolate methylprednisolone Systemic lupus erythematosus SLE

…tologic (lymphopenia), and serologic activity (SLEDAI-2K 6–8 on prednisolone 10 mg/day).Results In August 2024, anifrolumab 300 mg IV monthl…

PO:04:115 Successful combination rescue therapy in SLE complicated by TTP, lupus nephritis, sepsis, HLH with severe hyperinflammatory cardiomyopathy, and hyperhaemolysis

lupusscimed · abstract · 2026-03-01 · 15 matching annotations

97.9%

eculizumab rituximab anakinra caplicazumab caplacizumab methylprednisolone eculizumumab IV cyclophosphamide systemic lupus erythematosus SLE+1 more

… immunomodulation with combination targeted biologics—including eculizumab—may achieve full end-organ recovery despite life-threatening im…

PO:04:123 Pulmonary-renal crisis in systemic lupus erythematosus: a multimodal therapeutic approach

lupusscimed · abstract · 2026-03-01 · 15 matching annotations

98.6%

mycophenolate mofetil voclosporin valganciclovir Trimethoprim-sulfamethoxazole empagliflozin telmisartan atorvastatin cyclophosphamide rituximab hydroxychloroquine+3 more

…ximab, and plasmapheresis, followed by maintenance therapy with mycophenolate mofetil and voclosporin, can result in significant renal and pulmonary …